Search - tctmd.com

Displaying 281 - 300 of 492

Sort: Relevancy | Date

News Daily News

BMS 再见？新 DAPT 分析显示 DES 支架血栓形成率较低

Yael L. Maxwell

October 26, 2015

Presentation

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

Presenter: Dean J. Kereiakes

October 22, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

Presentation

Fixed and Modifiable Correlates of DES Thrombosis From a Large All-Comers Registry

Presenter: Bruce R. Brodie

October 08, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

Yael L. Maxwell

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

Advertisement

BMS 再见？新 DAPT 分析显示 DES 支架血栓形成率较低

Stent Thrombosis in DES or BMS in Patients Receiving Dual Antiplatelet Therapy

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

DAPT Study Subanalysis Focuses on EES Subgroup

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES 亚组研究：实践变化可能会进一步降低已处于低水平的支架血栓发生率

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Fixed and Modifiable Correlates of DES Thrombosis From a Large All-Comers Registry

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Transradial PCI May Attenuate Bivalirudin Benefits

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content